Skip to main content

Table 1 Frequency distribution of comorbidities, lifestyle factors and healthcare use among two study cohorts

From: New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case–control study in UK general practice

Characteristicb Both cohorts
N = 340,217a
n (%)
Non-exposed to low-dose apirin at start of follow-up cohort
N = 169,992a
n (%)
New users of low-dose aspirin at start of follow-up cohort
N = 170,225a
n (%)
Hypertension 80,269 (23.6) 55,228 (32.5) 25,041 (14.7)
Diabetes 46,994 (13.8) 12,365 (7.3) 34,629 (20.3)
COPD 16,677 (4.9) 7891 (4.6) 8786 (5.2)
IBD 4073 (1.2) 2061 (1.2) 2012 (1.2)
Depression 69,241 (20.4) 31,654 (18.6) 37,587 (22.1)
GI conditions 71,961 (21.2) 33,161 (19.5) 38,800 (22.8)
Record of prior colonoscopy, sigmoidoscopy or GI polyp 30,150 (8.9) 14,262 (8.4) 15,888 (9.3)
Smoking
 Non-smoker 150,723 (44.3) 79,726 (46.9) 70,997 (41.7)
 Current smoker 67,598 (19.9) 31,157 (18.3) 36,441 (21.4)
 Former smoker 103,536 (30.4) 48,552 (28.6) 54,984 (32.3)
 Unknown 18,360 (5.4) 10,557 (6.2) 7803 (4.6)
BMI (kg/m2)
 15–19 10,581 (3.1) 5976 (3.5) 4605 (2.7)
 20–24 86,326 (25.4) 47,714 (28.1) 38,612 (22.7)
 25–29 117,293 (34.5) 57,113 (33.6) 60,180 (35.4)
 ≥ 30 78,335 (23.0) 31,460 (18.5) 46,875 (27.5)
 Unknown 47,682 (14.0) 27,729 (16.3) 19,953 (11.7)
PCP visitsc
 0–1 11,729 (3.4) 5842 (3.4) 5887 (3.4)
 2–4 43,481 (12.8) 21,711 (12.8) 21,770 (12.8)
 5–9 98,550 (29.0) 49,238 (29.0) 49,312 (29.0)
 10–19 130,757 (38.4) 65,353 (38.4) 65,404 (38.4)
 ≥ 20 55,700 (16.4) 27,848 (16.4) 27,852 (16.4)
  1. BMI body mass index, COPD chronic obstructive pulmonary disorder, GI gastrointestinal, IBD inflammatory bowel disease
  2. aThe number of individuals in each of the two cohorts is slightly lower than the 170,336 originally identified because later information from a more recent version of the database showed that these patients had dropped out of the cohort (information that was not available in earlier versions of the database)
  3. bAll variables were measured any time before the start of follow-up except for PCP visits, which were collected in the year before the start of follow-up
  4. cIn the year before the start of follow-up (each new users of low-dose aspirin/non-exposed pair from the two cohorts was matched by number of PCP visits at the start of follow-up, in addition to matching by sex and age at start of follow-up)
\